Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
GALT's Cash to Debt is ranked higher than
89% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. GALT: No Debt )
GALT' s 10-Year Cash to Debt Range
Min: 1.59   Max: No Debt
Current: No Debt

Interest Coverage No Debt
GALT's Interest Coverage is ranked higher than
94% of the 460 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 88.77 vs. GALT: No Debt )
GALT' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: 0.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -816.21
GALT's ROE (%) is ranked lower than
61% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. GALT: -816.21 )
GALT' s 10-Year ROE (%) Range
Min: -830.47   Max: -63.92
Current: -816.21

-830.47
-63.92
ROA (%) -112.83
GALT's ROA (%) is ranked lower than
59% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. GALT: -112.83 )
GALT' s 10-Year ROA (%) Range
Min: -1711.47   Max: -50.18
Current: -112.83

-1711.47
-50.18
ROC (Joel Greenblatt) (%) -403466.67
GALT's ROC (Joel Greenblatt) (%) is ranked lower than
61% of the 732 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.50 vs. GALT: -403466.67 )
GALT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -403466.67   Max: -1857.06
Current: -403466.67

-403466.67
-1857.06
EBITDA Growth (%) 11.50
GALT's EBITDA Growth (%) is ranked higher than
77% of the 507 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. GALT: 11.50 )
GALT' s 10-Year EBITDA Growth (%) Range
Min: -22.1   Max: 11.5
Current: 11.5

-22.1
11.5
EPS Growth (%) 11.80
GALT's EPS Growth (%) is ranked higher than
76% of the 510 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. GALT: 11.80 )
GALT' s 10-Year EPS Growth (%) Range
Min: -33.2   Max: 35.1
Current: 11.8

-33.2
35.1
» GALT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GALT



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Net Cash 165.86
GALT's Price/Net Cash is ranked lower than
88% of the 214 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.10 vs. GALT: 165.86 )
GALT' s 10-Year Price/Net Cash Range
Min: 7.04   Max: 115.43
Current: 165.86

7.04
115.43
Price/Net Current Asset Value 165.86
GALT's Price/Net Current Asset Value is ranked lower than
95% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.80 vs. GALT: 165.86 )
GALT' s 10-Year Price/Net Current Asset Value Range
Min: 7.04   Max: 115.43
Current: 165.86

7.04
115.43
Forward Rate of Return (Yacktman) -1.92
GALT's Forward Rate of Return (Yacktman) is ranked higher than
63% of the 532 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. GALT: -1.92 )
GALT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -1.92

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:PHPN.Germany
Galectin Therapeutics Inc was incorporated in Nevada on January 26, 2001 as DTR-Med Pharma Corp. On May 10, 2001, DTR changed its name to Pro- Pharmaceuticals, Inc. On May 26, 2011, Pro-Pharmaceuticals, Inc. changed its name to Galectin Therapeutics Inc. Galectin Therapeutics is a development-stage company, which is engaged in drug development to create new therapies for cancer and fibrotic disease. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic function. The Company uses naturally occurring plant materials to create complex carbohydrates with specific molecular weights and pharmaceutical properties. The Company focuses on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The Company has two compounds in development, one intended to be used in cancer therapy and the other intended to be used in the treatment of liver fibrosis and fatty liver disease. These two compounds are produced from completely different natural starting materials, both possessing the property which lends itself to binding to and inhibiting galectin proteins. GM-CT-01, its product candidate for cancer therapy, is a proprietary linear polysaccharide polymer comprised of mannose and galactose that has a precisely defined chemical structure and is derived from a plant source. GR-MD-02, its other product for treatment of liver fibrosis and fatty liver disease with inflammation and fibrosis, is a proprietary complex polysaccharide polymer possessing both linear and globular structures, which also is derived from a plant source. Its competitors include major multinational pharmaceutical and chemical companies, specialized biotechnology firms and universities and other research institutions. The research, development, testing, manufacture, labeling, promotion, advertising, distribution, and marketing, among other things, of its products are extensively regulated by governmental authorities in the United States and other countries.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide